Alan Littman is a litigator at Goldman Ismail Tomaselli Brennan & Baum LLP with experience representing plaintiffs and defendants as lead trial lawyer in courts and arbitrations across the US. Littman counsels clients in a range of IP and commercial disputes, including patent infringement and trade secret matters. Littman’s clientele spans international clients across a variety of industries, including sports, pharma, medical devices, and technology.
Legal 500 Editorial commentary
Phone
312-881-5969
Email
Profile

Accolades

Chicago Elite

Profile

Position

Partner

Career

Alan is a proven first-chair trial attorney who specializes in complex trial litigation involving scientific and technical subject matter. As lead trial counsel, he has successfully tried multiple cases for plaintiffs and defendants to verdict throughout the country before judges, juries, and arbitrators. His cases involve a wide variety of subject matters, including patent infringement, trade secrets, securities, contract/fraud, product liability, ERISA, licensing, and other complex commercial matters. His cases also involve an array of scientific and technical subjects, including computer networking, medical devices, pharmaceutical products, video streaming, software design, solar cells, and computer hardware. Alan also brings a unique perspective from his experience working in several start-up companies. Prior to going into law, Alan was Vice President of Network Security for Citibank's online bank and was a Computer and Network Security Specialist for Iridium, a worldwide satellite telecommunications company. Alan graduated from the University of Chicago Law School with honors, served as editor-in-chief of The Law Review, and clerked on the United States Court of Appeals for the Seventh Circuit for Judge Frank H. Easterbrook.

Content supplied by Goldman Ismail Tomaselli Brennan & Baum LLP

Key clients

  • Edwards Lifesciences Corporation
  • Major League Baseball; MLB Advanced Media

Work highlights

Served as lead trial counsel defending Edwards Lifesciences Corporation in a multi-patent infringement lawsuit in the US District Court of Delaware.